What is Mosunetuzumab?

Mosunetuzumab (Mosunetuzumab) is a new type of antibody drug, which belongs to the field of immunotherapy and is used to treat some B Cell malignancies, especially diseases such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). What is unique about it is that its bispecific antibody structure can target two different proteins, CD3 and CD20, at the same time, thereby activating the patient's own immune system and guiding it to attack cancer cells.

The development of motuzumab represents a major advance in cancer treatment. Traditional chemotherapy drugs often kill rapidly dividing cells in a non-specific manner, but this can also damage normal cells, leading to serious side effects. In contrast, motuzumab reduces the risk of adverse reactions by precisely identifying and attacking tumor cells, thereby reducing damage to normal cells.

The mechanism of motuzumab is to connect T cells and tumor cells by binding to CD3 and CD20 proteins, prompting T cells to release toxic substances, such as perforin and cytotoxic enzymes, to directly attack cancer cells. In addition, it can activate other components of the immune system, such as natural killer cells (NK cells), to enhance anti-tumor immune responses.

Clinical trials have shown that motuzumab has potential efficacy in the treatment of someB cell malignancies. It has attracted widespread attention particularly in patients with refractory or relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Patients may benefit from this drug, especially those who have received other treatments without satisfactory results.

However, motuzumab may be associated with some side effects, including fever, chills, nausea, fatigue, and injection site reactions. Therefore, before using motuzumab, doctors will carefully evaluate the patient's condition and overall health, weigh the potential benefits and risks, and develop a personalized treatment plan.